Glafabra Therapeutics is considering a capital raise and is testing the waters under Regulation Crowdfunding.
Public source
Publisher name
Public post
Follow our story: https://lnkd.in/gF7ZsJdw Two months ago I started posting about Glafabra publicly, every day. Here's what surprised me. I expected the science to be th…
Company
Glafabra Therapeutics
Gene therapy for Fabry and other enzyme deficiencies - one dose for years long durability and patient freedom
- Industry
- Biotechnology Research
- Company size
- 2–10 employees
About Glafabra Therapeutics
Glafabra is a biotherapeutics development company focused on bringing into the clinic our Live-cel(TM) technology for cell-based gene therapy (Cb-GT). Our approach for Fabry Disease provides a 130x improvement in effectiveness for patients, when compared to the standard of care of enzyme replacement therapy. We are bringing to the clinic a therapy that is long acting. Where just one dose, can last for years, not weeks.
See moreLatest activity
Latest activity from Glafabra Therapeutics
9 signals
Legal & Regulatory
Glafabra Therapeutics is considering a capital raise and is
Capital & Finance
Glafabra Therapeutics is considering a capital raise under Regulation Crowdfunding.
Capital & Finance
Glafabra Therapeutics is registering interest in a crowdfunding campaign to test the waters for a capital raise.
Discover more
Similar signals
Similar public activity from other companies.
Capital & Finance
Mahzi Therapeutics
Mahzi Therapeutics raised capital to the community on Wefunder
Capital & Finance
Sarcomatrix
Sarcomatrix Therapeutics is raising capital under Regulation D Rule 506(c) for its early-stage therapeutic candidate programs.
Capital & Finance
Akelos Inc
Akelos Inc is raising capital to expand FDA testing
Capital & Finance
BioCrowd
BioCrowd is funding $90 million into three science and technology centers for 5 years.
Capital & Finance
TILT Biotherapeutics Ltd